Can Rite Aid Defy the Odds?

Heading into earnings, shareholders are probably hoping for a strong performance from the drugstore chain, but analysts are expecting mediocre results. Can Rite Aid defy the odds and soar this year, or should investors look toward CVS and Walgreen for outsized returns?

Apr 8, 2014 at 5:30PM

Images

Source: Wikimedia Commons

April 10 is bound to be a big day for shareholders of Rite Aid (NYSE:RAD). In anticipation of the company's fiscal fourth-quarter earnings, shares of the drugstore chain have done anything but well. Even though the company's closing price on April 4 marked a nearly 23% jump in share price year to date, Rite Aid's stock has plummeted 6% since the beginning of March.

With this short-term concern over the business' prospects impacting the stock, is now an attractive time to go all-in, or is Mr. Market signaling that the company's outlook is anything but bright?

Analysts have low but mixed expectations for Rite Aid
For the quarter, analysts expect Rite Aid to report revenue of $6.54 billion. If this forecast is correct, it would signify a 1% increase in sales compared to the $6.46 billion the company reported in the year-ago quarter. According to the company's monthly sales release, Rite Aid's main growth driver for the quarter will probably be its higher comparable-store sales, partially offset by fewer locations in operation.

While Mr. Market seems positive about Rite Aid's top-line growth, the same cannot be said about profitability. For the quarter, analysts expect the company's earnings per share to come in around $0.04. This represents a 69% drop compared to the $0.13 per share the company reported in the same quarter last year; it would likely be attributed to a greater share count but could also be chalked up to higher costs.

  Forecast Fourth Quarter Last Year Expected Difference
Revenue $6.54 billion $6.46 billion 1.2%
EPS $0.04 $0.13 -69.2%

Source: Yahoo! Finance and Rite Aid

Between the 2013 and 2014 third quarters, Rite Aid increased its share count by roughly 7%. If this trend continues into its fourth quarter, it could be one of the main contributors to the company's lower profits.

Is Rite Aid a strong buy heading into earnings?
In spite of the expected earnings shortfall, Rite Aid could still prove to be an excellent prospect heading into earnings. However, to know if this is the case, we should delve a little into the recent performances of some of the business' competitors: CVS Caremark (NYSE:CVS) and Walgreen (NASDAQ:WBA).

Picture

Source: CVS

In its most recent quarter, CVS reported a nearly 5% gain in revenue from $31.4 billion to $32.8 billion. The main driver behind the company's attractive growth was its comparable-store sales, which increased 4% compared to the same quarter a year earlier. This stemmed from a 6.8% improvement in the company's comparable-pharmacy sales and higher prescriptions but was partially offset by lower front-end sales.

(CVS) Actual Results Year-Ago Results Difference
Revenue $32.8 billion $31.4 billion 4.5%
EPS $1.05 $0.90 16.7%

Source: CVS

Looking at profitability, CVS did even better. For the quarter, the company saw its earnings per share rise 17% from $0.90 to $1.05. In part, this was due to a 4% reduction in shares outstanding. But it was also attributed to depressed income in 2012 that management chalked up to a loss from the early extinguishment of debt.

Picture

Source: Walgreen

During its most recent quarter, Walgreen did just as well in terms of revenue but came up shy on earnings. For the quarter, management reported a 5% improvement in the company's revenue from $18.6 billion to $19.6 billion. Just as in the case of CVS, Walgreen's top-line improvement was attributed to a 4.3% jump in comparable-store sales.

(Walgreen) Actual Results Year-Ago Results Difference
Revenue $19.6 billion $18.6 billion 5.4%
EPS $0.78 $0.79 -1.3%

Source: Walgreen

Profits, on the other hand, did not quite measure up. For the quarter, earnings per share came in at $0.78, $0.01 below last year's results. Despite seeing higher revenue, the company saw its costs increase. This was largely driven by its cost of goods sold rising from 69.9% of sales to 71.2% because of a lower last in, first out provision compared to last year. Another contributor to the company's lackluster earnings was a 1% increase in shares outstanding.

Foolish takeaway
Based on the data provided, it looks like analysts are fairly pessimistic about Rite Aid's prospects heading into its fourth quarter. Taking this into consideration, combined with the strong performance generated by CVS and Walgreen in their most recent quarters, Rite Aid might not be the best prospect in the drugstore industry. Among these, the data suggests that CVS might be the best performer, having trounced both revenue and earnings from the prior year.

Boost your 2014 returns with The Motley Fool's top stock
In spite of the mediocre performance expected from Rite Aid, shares have rallied over the past year, making it one of the best holdings lately. Is it possible that the business can defy the odds and be the best company to hold for 2014, or is there a better opportunity for the Foolish investor?

There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Daniel Jones has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers